Global Brain Ischemia Market Size, Share, Forecast Report, 2020-2027

Brain Ischemia Market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 606.73 million in 2018 and is projected to register a 6.57% CAGR over the forecast period.

Brain ischemia occurs when there is insufficient blood flow to the brain to meet the metabolic demand. This condition leads to poor oxygen supply or cerebral hypoxia and hence leading to the death of the brain tissues or brain ischemia.

Factors such as the increasing burden of ischemic strokes and growth in the geriatric population which is prone to brain ischemia are expected to drive the market growth. According to a survey carried out by the World Health Organization (WHO) in 2019, ischemic stroke is the third most cause of death in the adult population. Moreover, the rising focus of companies for developing drugs for the treatment of brain ischemia is also expected to boost market growth.

However, factors such as the stringent government regulations and limited availability of the treatment options are expected to hamper the market growth.

Segmentation

The global brain ischemia market has been segmented into condition type, treatment, end users, and region.

Based on condition type, the global brain ischemia market has been segmented into focal brain ischemia and global brain ischemia.

The global brain ischemia market, by treatment, has been segmented into angioplasty, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and others.

The global brain ischemia market, by end user, has been segmented into hospitals & clinics, research & academic institutes, and others.
Key Players

Taxus Cardium (US), Edwards Lifesciences Corporation (US), Boston Scientific Corporation (US), Merck KGaA (Germany), Medtronic (Ireland), Cook Medical (US), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Abbott (US), Becton, Dickinson and Company (US), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK) are some of the key players operating in the global brain ischemia market.

Global Brain Ischemia Market, by Condition Type

• Focal Brain Ischemia
• Global Brain Ischemia

Global Brain Ischemia Market, by Treatment

• Angioplasty
• Beta-Blockers
• Angiotensin-Converting Enzyme (ACE) Inhibitors
• Others

Global Brain Ischemia Market, by End User

• Hospitals and Clinics
• Research and Academic Institutes
• Others